Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: 3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) Positron Emission Tomography as an In Vivo Biomarker of inhibition of CDK 4/6-Rb pathway by Palbociclib in a patient derived bladder tumor

Fig. 2

Study Protocol. Twenty-four NSG mice bearing patient derived xenografts of a well-characterized bladder tumor were randomized into 4 treatment groups: Control (n = 6); palbociclib (n = 6); temozolomide (n = 6); and palbociclib plus temozolomide (n = 6) and treated with two cycles of therapy or vehicle

Back to article page